UPDATE: Jefferies Starts Bellerophon Therapeutics (BLPH) at Buy

(updating comment)

Jefferies analyst Chris Howerton initiates coverage on Bellerophon Therapeutics (NASDAQ: BLPH) with a Buy rating and a price target of $19.00.

The analyst comments "BLPH is a company developing the INOpulse inhaled nitrous oxide (iNO) system for rare cardiopulmonary disorders. We like INOpulse in its lead indication pulmonary hypertension-pulmonary fibrosis (PH-PF), and project un-adjusted sales of $600M in 2033, w/pot'l upside from label expansion. While we don't give credit to INOpulse in COVID-19, we do see potential approval in the indication as a significant de-risking for PH-PF."

For an analyst ratings summary and ratings history on Bellerophon Therapeutics click here. For more ratings news on Bellerophon Therapeutics click here.

Shares of Bellerophon Therapeutics closed at $12.31 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• McGraw Hill (MH) PT Raised to $15 at UBS